Fig. 4: T cells from HBV+ non-liver cancer patients have been subjected to stronger immunosuppression than their HBV– counterparts.
From: Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer
A UMAP projection of PBMCs from 6 ESCC patients, colored by cell type. Each dot represents a cell. B UMAP projection of PBMCs from 6 ESCC patients, colored by patient. Each dot represents a cell. C Scatter plot of the cytotoxicity score and exhaustion score of CD8+ TEFF showed two distinct subsets, namely Exhaustionhi T and Exhaustionlow T. Vertical dashed line represents exhaustion score = 0. D Box plot of the fraction of Exhaustionhi T in CD8+ TEFF in HBV– non-liver cancer patients and HBV+ non-liver cancer patients. p-value was determined by Kruskal–Wallis test. E Box plots of cytotoxicity score of CD8+ TEFF in HBV– non-liver cancer patients and HBV+ non-liver cancer patients. p-value was determined by Student’s t-test.
